Kyntra Bio, Inc. (KYNB) stock
Close on Nov 17, 2026Market cap $8.26MP/E 0.0Yield –
Earnings
Kyntra Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Kyntra Bio's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026after the close | -$1.50M | -215.4% | $2.96 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 11, 2026after the close | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 16, 2026after the close | $1.30M | -58.1% | -$3.51 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025after the close | $1.10M | -97.6% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025after the close | $1.30M | -97.4% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025after the close | $2.70M | -95.2% | $0.05 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 17, 2025after the close | $3.10M | -88.6% | -$0.08 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024after the close | $46.30M | +15.5% | -$0.17 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024after the close | $50.60M | +14.2% | -$0.16 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 6, 2024after the close | $55.90M | +54.4% | -$0.33 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 26, 2024after the close | $27.10M | -21.2% | -$0.57 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 6, 2023after the close | $40.10M | +155.4% | -$0.65 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 7, 2023after the close | $44.30M | +48.7% | -$0.90 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023after the close | $36.20M | -40.5% | -$0.81 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 27, 2023after the close | $34.40M | +108.5% | -$0.70 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 7, 2022after the close | $15.70M | -89.9% | -$0.98 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022after the close | $29.80M | – | -$0.78 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022after the close | $60.80M | – | -$0.68 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022after the close | $16.50M | – | -$1.45 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021after the close | $156.00M | – | $0.54 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 9, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 10, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 1, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Kyntra Bio guided for has been reported
Guidance history
Every forecast Kyntra Bio put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 12, 2024 | expected full year roxadustat net sales in China1 by FibroGen and the JDE | FY2024 | $330.00M – $350.00M | New |
| Nov 12, 2024 | net product revenue under U.S. GAAP | FY2024 | $135.00M – $150.00M | Reaffirmed |
| Aug 6, 2024 | roxadustat net sales in China | FY2024 | $320.00M – $350.00M | Raised |
| Aug 6, 2024 | net product revenue | FY2024 | $135.00M – $150.00M | Raised |
| May 6, 2024 | roxadustat net sales in China | FY2024 | $300.00M – $340.00M | New |
| May 6, 2024 | net product revenue under U.S. GAAP | FY2024 | $120.00M – $135.00M | Reaffirmed |
| Feb 26, 2024 | net product revenue under U.S. GAAP | FY2024 | $120.00M – $135.00M | New |
| Nov 7, 2022 | ending cash balance | FY2022 | $380.00M – $410.00M | Raised |
| Aug 8, 2022 | ending cash balance | FY2022 | $330.00M – $360.00M | Raised |
| May 9, 2022 | ending cash balance | FY2022 | $310.00M – $340.00M | Raised |
| Feb 28, 2022 | ending cash | FY2022 | $270.00M – $300.00M | New |
| Nov 9, 2021 | ending balance of cash, cash equivalents, investments, and accounts receivable | FY2021 | $580.00M – $610.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Kyntra Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- News
- Results
- News
- News
- Results
- Results
- Update
- Results
- Results
- Results
See a number that looks wrong?